Clinical Trial

Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer

Study acronym: LumOnate
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This phase 1b trial is designed to evaluate the safety and tolerability of olaparib in combination with 177Lutetium-Prostate Specific Membrane Antigen (177 Lu-PSMA) and pembrolizumab in patients with metastatic castration resistant prostate cancer (mCRPC).
Trial Details
NCT Number NCT07090369
Lead Sponsor Peter MacCallum Cancer Centre, Australia
Conditions Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Enrollment 20 participants
Start Date 2025-11-01
Primary Completion 2028-12-01 (estimated)
Study Completion 2028-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-29